$BBIO BridgeBio gets FDA priority review for its achondroplasia drug.

By Nexqual Desk ·

Tickers: $BBIO

$BBIO BridgeBio gets FDA priority review for its achondroplasia drug.

• The FDA set a PDUFA target action date of February 4, 2027 for the drug's approval.

• The Phase 3 study showed a +2.10 cm/yr improvement in annualized height velocity.

Source: SEC 8-K, Oct 13, 2026.

0 likes

Posted on Nexqual Sonar — the social network for the stock market. Not financial advice.

Data source: Nexqual. Last updated: October 16, 2026 at 04:22 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt